We acquire, develop and license innovative drugs to treat pandemic infections. We have expanded to develop a broader portfolio of new therapies to meet the rising burden of critical priority infectious disease. Based at Alderley Park in the North West of England, our work addresses unmet patient needs and will bring new portfolio of drugs into clinical trials to treat patients suffering from life-threatening infections.
Breaking News
Tackling underlying respiratory conditions for this pandemic and next
During the COVID-19 pandemic, one of the many phrases that has become irreversibly etched onto the minds of the British public – along with social distancing, self-isolation and R number – is…
Infex partners with Alderley Analytical to provide PK and ADA analysis for RESP-X program
Infex Therapeutics has today announced a deal with Alderley Analytical, to support PK and ADA analysis of Infex’s RESP-X program.
Latest News
Tackling underlying respiratory conditions for this pandemic and next
During the COVID-19 pandemic, one of the many phrases that has become irreversibly etched…
Infex partners with Alderley Analytical to provide PK and ADA analysis for RESP-X program
Infex Therapeutics has today announced a deal with Alderley Analytical, to support PK and…
Deals agreed as Infex’s resistance bypass drug program heads for clinic
Infex Therapeutics has appointed Pharmaron to help progress its MET-X program which…
Infex focuses on pandemic preparedness with Covid patent
Infex Therapeutics has filed for a UK patent for a novel therapy designed to tackle all…
Introducing Infex Therapeutics
The organisation leading UK efforts to tackle the health crisis around our dwindling…
Major boost in global fight against antimicrobial resistance as AMR Centre receives share of Strength in Places Fund award
The AMR Centre has combined forces to attract much needed investment to combat the global…
The AMR Centre signs agreement to co-develop treatment for gonorrhoea
The AMR Centre (AMRC) has today announced a multi-year co-development agreement with…